Lantheus
LNTH
Market cap $5.48B

81.31 USD

-2.52

3.01%

At close Jul 11, 4:00 PM EDT

After hours

81.28

-0.03

0.04%

1 day

-3.01%

5 days

1.23%

1 month

0.69%

3 months

-20.28%

6 months

-14.09%

Year to date

-8.43%

1 year

-34.23%

5 years

463.09%

10 years

1,081.83%

About: Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.

Employees: 808

Healthcare Drug Manufacturers - Specialty & Generic

0

Funds holding %

of 7,312 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

87% more first-time investments, than exits

New positions opened: 84 | Existing positions closed: 45

60% more call options, than puts

Call options by funds: $43.3M | Put options by funds: $27.1M

25% more funds holding in top 10

Funds holding in top 10: 8 [Q4 2024] → 10 (+2) [Q1 2025]

14% more capital invested

Capital invested by funds: $6.68B [Q4 2024] → $7.64B (+$958M) [Q1 2025]

13% more repeat investments, than reductions

Existing positions increased: 195 | Existing positions reduced: 173

7.05% more ownership

Funds ownership: 107.38% [Q4 2024] → 114.43% (+7.05%) [Q1 2025]

6% more funds holding

Funds holding: 481 [Q4 2024] → 511 (+30) [Q1 2025]

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$109

34%

upside

Avg. target

$113

39%

upside

High target

$117

44%

upside

2 analyst ratings

2 positive

100%

0 neutral

0%

0 negative

0%

B. Riley Securities Justin Walsh	34%upside $109	Buy Maintained	23 Jun 2025
Truist Securities Richard Newitter	44%upside $117	Buy Maintained	8 May 2025

See Analyst Rankings

Financial journalist opinion

Lantheus Seems Worth The (Very Real) Risks

Lantheus Holdings offers a compelling bull case with PYLARIFY and DEFINITY driving valuation and strong growth prospects. A headline multiple of 12x 2025 earnings obscures real risks around PYLARIFY revenue, pricing, and rising competition. PYLARIFY's dominance in prostate cancer imaging has fueled massive stock gains, but new competitors like Telix and Blue Earth threaten its market share.

Lantheus Seems Worth The (Very Real) Risks

Lantheus Announces Presentations to be featured at the 2025 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting

BEDFORD, Mass., June 11, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, announced the presentation of new data highlighting two oncology radiodiagnostic agents will be presented at the upcoming 2025 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, taking place June 21-24, 2025, in New Orleans, LA.

Lantheus Announces Presentations to be featured at the 2025 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting

Lantheus to Present at the 2025 Truist Securities MedTech Conference

BEDFORD, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced Brian Markison, Chief Executive Officer, will present at the 2025 Truist Securities MedTech Conference at 8:40 a.m. ET on Tuesday, June 17.

Lantheus to Present at the 2025 Truist Securities MedTech Conference

PharmaLogic Announces Appointment of Etienne Montagut as President and Chief Executive Officer

BOCA RATON, Fla. , June 2, 2025 /PRNewswire/ -- PharmaLogic Holdings Corp.

PharmaLogic Announces Appointment of Etienne Montagut as President and Chief Executive Officer

Lantheus Holdings, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - LNTH

NEW YORK, NY / ACCESS Newswire / May 23, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Lantheus Holdings, Inc. ("Lantheus Holdings, Inc.") (NASDAQ:LNTH) concerning possible violations of federal securities laws. On May 7, 2025, Lantheus reported its financial results for the first quarter of 2025.

Lantheus Holdings, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - LNTH

Lantheus Holdings, Inc. (LNTH) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights

NEW YORK, NY / ACCESS Newswire / May 22, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Lantheus Holdings, Inc. ("Lantheus Holdings, Inc.") (NASDAQ:LNTH) concerning possible violations of federal securities laws. On May 7, 2025, Lantheus reported its financial results for the first quarter of 2025.

Lantheus Holdings, Inc. (LNTH) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights

Did Lantheus Holdings, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - LNTH

NEW YORK, NY / ACCESS Newswire / May 21, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Lantheus Holdings, Inc. ("Lantheus Holdings, Inc.") (NASDAQ:LNTH) concerning possible violations of federal securities laws. On May 7, 2025, Lantheus reported its financial results for the first quarter of 2025.

Did Lantheus Holdings, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - LNTH

Lantheus Holdings, Inc. (LNTH) Shareholders May Have Been Affected by Fraud - Levi & Korsinsky Investigates

NEW YORK, NY / ACCESS Newswire / May 20, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Lantheus Holdings, Inc. ("Lantheus Holdings, Inc.") (NASDAQ:LNTH) concerning possible violations of federal securities laws. On May 7, 2025, Lantheus reported its financial results for the first quarter of 2025.

Lantheus Holdings, Inc. (LNTH) Shareholders May Have Been Affected by Fraud - Levi & Korsinsky Investigates

LNTH ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Lantheus Holdings, Inc.

NEW YORK, NY / ACCESS Newswire / May 19, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Lantheus Holdings, Inc. ("Lantheus Holdings, Inc.") (NASDAQ:LNTH) concerning possible violations of federal securities laws. On May 7, 2025, Lantheus reported its financial results for the first quarter of 2025.

LNTH ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Lantheus Holdings, Inc.

Shareholder Rights Advocates at Levi & Korsinsky Investigate Lantheus Holdings, Inc. (LNTH) Regarding Possible Securities Fraud Violations

NEW YORK, NY / ACCESS Newswire / May 16, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Lantheus Holdings, Inc. ("Lantheus Holdings, Inc.") (NASDAQ:LNTH) concerning possible violations of federal securities laws. On May 7, 2025, Lantheus reported its financial results for the first quarter of 2025.

Shareholder Rights Advocates at Levi & Korsinsky Investigate Lantheus Holdings, Inc. (LNTH) Regarding Possible Securities Fraud Violations

See News Rankings

Charts implemented using Lightweight Charts™